PT - JOURNAL ARTICLE AU - TOMOFUMI NARUSE AU - SOUICHI YANAMOTO AU - MITSUNOBU OTSURU AU - NOBUHIRO YAMAKAWA AU - TADAAKI KIRITA AU - YUKARI SHINTANI AU - TATSUSHI MATSUMURA AU - MASAYA OKURA AU - MASASHI SASAKI AU - YOSHIHIDE OTA AU - SHIN-ICHI YAMADA AU - HIROSHI KURITA AU - MASAHIRO UMEDA AU - JAPAN ORAL ONCOLOGY GROUP (JOOG) TI - Multicenter Retrospective Study of Weekly Cetuximab Plus Paclitaxel for Recurrent or Metastatic Oral Squamous Cell Carcinoma AID - 10.21873/anticanres.15395 DP - 2021 Nov 01 TA - Anticancer Research PG - 5785--5791 VI - 41 IP - 11 4099 - http://ar.iiarjournals.org/content/41/11/5785.short 4100 - http://ar.iiarjournals.org/content/41/11/5785.full SO - Anticancer Res2021 Nov 01; 41 AB - Background/Aim: This study was conducted to compare the efficacy and safety of the weekly cetuximab plus paclitaxel (wCmab-PTX) regimen with those of the EXTREME regimen in patients with recurrent or metastatic oral squamous cell carcinoma (R/M OSCC). Patients and Methods: This multicenter retrospective study involved a chart review of the clinical records of R/M OSCC patients treated with wCmab-PTX in each institution between January 2013 and December 2017. Data were collected, and the efficacy, safety, and treatment outcomes were analyzed. Results: The best overall response and disease control rates were 48.4% and 61.3%, respectively. The median PFS and OS were 6 and 13 months, respectively. There was no significant difference in prognosis with or without previous platinum administration. The grade 3-4 adverse events were leukopenia (16.1%), followed by acne-like rash (12.9%), and neutropenia (9.7%). All adverse events, excluding more than grade 3 infusion reactions, were tolerable and manageable. Conclusion: wCmab-PTX may be considered as a treatment option for R/M patients with OSCC that is refractory to platinum-based chemotherapy, or progressive disease after receiving chemotherapy.